Corona Remedies IPO
Corona Remedies IPO
Overview
Corona Remedies IPO is a book build issue of ₹655.37 crores. The issue is entirely an offer for sale of 0.62 crore shares of ₹655.37 crore. Corona Remedies IPO opens for subscription on Dec 8, 2025 and closes on Dec 10, 2025. The allotment for the Corona Remedies IPO is expected to be finalized on Dec 11, 2025. Corona Remedies IPO will list on BSE, NSE with a tentative listing date fixed as Dec 15, 2025. Corona Remedies IPO price band is set at ₹1008.00 to ₹1062.00 per share . The lot size for an application is 14. The minimum amount of investment required by an retail is ₹14,868 (14 shares) (based on upper price). The lot size investment for sNII is 14 lots (196 shares), amounting to ₹2,08,152, and for bNII, it is 68 lots (952 shares), amounting to ₹10,11,024. JM Financial Ltd. is the book running lead manager and Bigshare Services Pvt.Ltd. is the registrar of the issue.
Total Shares
61,71,101
Issue Size
₹655.37 Cr
Price Band
₹1008 – ₹1062
Lot Size
14 shares
Min. Investment
₹14,868
Max. Investment
₹1,93,284
Open Date
08 Dec, 2025
Close Date
10 Dec, 2025
Allotment
11 Dec, 2025
Listing
15 Dec, 2025
Max. Investment
₹1,93,284
Announced
08 Dec, 2025
Opening Date
08 Dec, 2025
Closing Date
10 Dec, 2025
Basis of Allotment
11 Dec, 2025
Initiation of Refunds
12 Dec, 2025
Credit of Shares
12 Dec, 2025
Listing Date
15 Dec, 2025
Live GMP
Est. Listing: ₹1319
Apply via UPI in 5 minutes
Choose your broker • Zero commission on IPO
About Corona Remedies IPO
Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas.
As of June 30, 2025, the company's diverse portfolio includes 71 brands across therapeutic areas like women’s healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals (including vitamins/minerals/nutrition, gastrointestinal, and respirato
Corona Remedies IPO Share Price
Issue Breakdown
Shareholding
Dilution: 0.0% increase in shares
Corona Remedies IPO Promoters Holding
Corona Remedies IPO Financial Health
Corona Remedies Ltd.'s revenue increased by 18% and profit after tax (PAT) rose by 65% between the financial year ending with March 31, 2025 and March 31, 2024.
Corona Remedies IPO Lot Size
Investors can bid for a minimum of 14 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Individual Investors (Retail) and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 14 | ₹14,868 |
| Retail (Max) | 13 | 182 | ₹1,93,284 |
| S-HNI (Min) | 14 | 196 | ₹2,08,152 |
| S-HNI (Max) | 67 | 938 | ₹9,96,156 |
| B-HNI (Min) | 68 | 952 | ₹10,11,024 |
(All values in CR)
Corona Remedies IPO Valuations
KPI as of Mon, Mar 31, 2025.
| Metric | Value |
|---|---|
| ROE | 27.50 |
| ROCE | 41.32 |
| Debt/Equity | 0.10 |
| RoNW | 24.65 |
| PAT Margin | 12.49 |
| EBITDA Margin | 20.55 |
| Price to Book Value | 10.71 |
| Market Capitalization | 6,495.20 |
(All values in CR)
Corona Remedies IPO Strength & Risk
Corona Remedies IPO Strength:
Operates as a pharmaceutical formulations company with a wide therapeutic portfolio.
Serves multiple healthcare segments such as women’s health, cardiology, diabetes care, urology, and pain management.
Benefits from strong domestic market presence supported by an extensive distribution network.
Maintains in-house manufacturing facilities, ensuring better control over quality and supply.
Pharma demand is generally stable and less affected by economic cycles.
Strong field force and marketing capabilities enhance brand visibility and prescription reach.
Corona Remedies IPO Risk:
IPO is structured as a complete offer-for-sale, bringing no new capital into the company.
Growth plans rely entirely on internal resources rather than IPO funding.
Faces intense competition from established pharmaceutical companies.
Highly dependent on regulatory approvals, pricing policies, and compliance requirements.
Vulnerable to fluctuations in raw-material costs and supply-chain constraints.
Margin pressure may arise from competitive pricing and industry-wide challenges.
Listing performance may depend heavily on market sentiment and consistent post-IPO execution.
Corona Remedies IPO Subscriptions Status
Corona Remedies IPO subscribed 9.93 times. The public issue subscribed 6.86 times in the retail category, 1.76 times in QIB (Ex Anchor), and 28.34 times in the NII category by December 9, 2025 6:04:47 PM (Day 2).
| Investor Category | Subscription (times) | Shares Offered | Shares bid for | Total Amount (Rs Cr.) |
|---|---|---|---|---|
| Anchor | 1.00 | 18,34,804 | 18,34,804 | 194.856 |
| QIB (Ex Anchor) | 1.76 | 12,21,729 | 21,48,468 | 228.167 |
| Non-Institutional Buyers | 28.34 | 9,16,960 | 2,59,82,488 | 2 |
| bNII (bids above ₹10L) | 29.02 | 6,11,307 | 1,77,42,690 | 1 |
| sNII (bids below ₹10L) | 26.96 | 3,05,653 | 82,39,798 | 875.067 |
| Retail | 6.86 | 21,39,573 | 1,46,70,026 | 1 |
| Employees | 4.35 | 58,036 | 2,52,532 | 26.819 |
| Total | 9.93 | 43,36,298 | 24,30,53,514 | 4 |
Corona Remedies IPO GMP
Corona Remedies IPO last GMP is ₹257, last updated Dec 9th 2025 12:56 PM. With the price band of 1062.00, Corona Remedies IPO's estimated listing price is ₹1319 (cap price + today's GMP).The expected percentage gain/loss per share is 24.20%. >> Corona Remedies IPO Retail Subject to Sauda: ₹2700 >> Corona Remedies IPO Small HNI Subject to Sauda: ₹37800 The lowest GMP is ₹0.00, while the highest GMP is ₹365.00.
Last updated 09 Dec, 2025 · Source: aggregated grey-market dealers
| Date | IPO Price | GMP | Sub2 Sauda | Est. Listing | Est. Profit | Updated |
|---|---|---|---|---|---|---|
| 09 Dec, 2025 | 1062 | ₹257▼ | 2700/37800 | ₹1319 (24.20%) | 3598 | 09 Dec, 2025 |
| 08 Dec, 2025 | 1062 | ₹262▼ | 2800/39200 | ₹1324 (24.67%) | 3668 | 08 Dec, 2025 |
| 07 Dec, 2025 | 1062 | ₹290▼ | 3100/43400 | ₹1352 (27.31%) | 4060 | 07 Dec, 2025 |
| 06 Dec, 2025 | 1062 | ₹305▼ | 3200/44800 | ₹1367 (28.72%) | 4270 | 06 Dec, 2025 |
| 05 Dec, 2025 | 1062 | ₹365 | 3900/54600 | ₹1427 (34.37%) | 5110 | 05 Dec, 2025 |
| 04 Dec, 2025 | 1062 | ₹365▲ | 3900/54600 | ₹1427 (34.37%) | 5110 | 04 Dec, 2025 |
| 03 Dec, 2025 | 1062 | ₹307▲ | 3300/46200 | ₹1369 (28.91%) | 4298 | 03 Dec, 2025 |
| 02 Dec, 2025 | 0 | ₹0 | - | ₹ (%) | - | 02 Dec, 2025 |
Disclaimer: GMP is an unofficial signal from grey-market dealers and is not regulated by SEBI. Use it alongside subscription data and other research for informed decision-making.
How to Apply for Corona Remedies IPO
Login to Your Trading App
Open Zerodha, Upstox, Groww, Angel One, or any brokerage app.
Go to IPO Section
Find Corona Remedies IPO under the IPO section. Select it and enter your bid details — choose lot size and price (cut-off price recommended).
Enter UPI ID and Submit
Provide your UPI ID linked to your bank account and submit the application.
Approve Mandate on UPI App
Open your UPI app (Google Pay, PhonePe, Paytm, BHIM) and approve the IPO payment request.
Application Confirmed
Your funds will be blocked in your account until the IPO allotment process is completed.